The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism by Pickhard, Anja et al.
Oncotarget5428www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 14
The response of head and neck squamous cell carcinoma to 
cetuximab treatment depends on Aurora kinase A polymorphism 
Anja Pickhard1,*, Michael Siegl1,*, Alexander Baumann1, Maximilian Huhn1, Markus 
Wirth1, Rudolf Reiter2, Martina Rudelius3, Guido Piontek1 and Gero Brockhoff4
1 Department of Otolaryngology Head and Neck Surgery, Technical University of Munich, Muenchen, Germany
2 Department of Otolaryngology Head and Neck Surgery, Section of Phoniatrics and Pedaudiology, University of Ulm, Ulm, 
Germany
3 Institute of Pathology, Julius-Maximilians-University and Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany
4 Department of Gynecology and Obstetrics; University of Regensburg, Regensburg, Germany
* Equal contribution
Correspondence to: Anja Pickhard, email: a.pickhard@lrz.tum.de
Keywords: Aurora kinase A polymorphism, Aurora kinase B, cetuximab, HNSCC
Received: May 1, 2014 Accepted: June 17, 2014 Published: June 18, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Objectives: The aim of this study was to evaluate the efficiency of cetuximab-
based anti-EGFR treatment and Aurora kinase A / B knockdown as a function of Aurora 
kinase polymorphism in HNSCC cell lines. 
Materials and methods: First, protein expression of Aurora kinase A / B and EGFR 
and Aurora kinase A polymorphism were studied in tumour samples. 
The survival and proliferation of Aurora kinase A homo- (Cal27) and heterozygous 
(HN) HNSCC cell lines was evaluated using a colony formation assay and a flow 
cytometric assay. Also, aneuploidy was determined. EGFR signalling pathway were 
visualised by western blotting. 
Results: Immunohistochemistry revealed the overexpression of Aurora kinase A / 
B in HNSCC. The knockdown of each kinase caused a significant decrease in clonogenic 
survival, independent of Aurora kinase A polymorphism. In contrast, cetuximab 
treatment impaired clonogenic survival only in the Aurora kinase A-homozygous cell 
line (Cal27). 
Conclusion: This study provides in vitro evidence for the predictive value of 
Aurora kinase A polymorphism in the efficiency of cetuximab treatment. Resistance to 
cetuximab treatment can be overcome by simultaneous Aurora kinase A/B knockdown. 
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth most common cancer worldwide [1]. Despite 
recent advances in surgery and adjuvant treatment options, 
an overall cure is only achieved in less than 50% of cases. 
In contrast to many other malignant diseases, HNSCC 
rarely shows distant metastases at the time of diagnosis 
but shows a higher incidence of systemic spread [2]. 
Furthermore, patients with recurrent or metastatic disease 
have a poor prognosis, with a mean survival of 6-10 
months [2]. 
The overexpression of epidermal growth factor 
receptor (EGFR) in HNSCC is often caused by gene 
amplification [3], and this elevated expression is 
associated with a poor disease outcome and an increased 
risk of metastasis [4, 5]. The extension of the standard 
first-line therapy regimen of cisplatin/5-fluorouracil 
with tumour treatment using the monoclonal antibody 
C225 (cetuximab) has increased the rate of objective 
responses and also improved the progression-free (PFS) 
and overall survival (OS) of patients with progressive / 
metastatic HNSCC [6, 7]. Nevertheless, the individual 
patient response to this target specific treatment varies 
significantly and is not predictable. 
DNA gains on chromosome 20q are frequently 
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found in HNSCC [8, 9] and are associated with lymph 
node metastasis, as shown by array-based comparative 
genomic hybridisation [10]. The Aurora kinase A (AurkA) 
encoding region is located on 20q13.2 and maps close to 
the critical region of DNA gain [11]. Aurora kinases A 
and B (AurkA and AurkB) are highly conserved serine/
threonine kinases that play essential but distinct roles in 
mitosis. Specifically, AurkA is required for the assembly 
of the mitotic spindle and accumulates on centrosomes at 
the spindle poles during prophase until metaphase [12]. 
Furthermore, the up-regulation of AurkA leads to abnormal 
centrosome numbers and the induction of aneuploidy [13, 
14], which is a very frequent event in HNSCC and found 
in up to 90% of all tumours [15]. In contrast, AurkB is 
required for mitotic progression and cytokinesis and 
colocalises with inner centromeric protein (INCENP) 
and survivin at the centromeres of chromosomes during 
cytokinesis. AurkB is involved in chromosome alignment 
at the spindle midzone during the metaphase / anaphase 
transition [12, 16]. A T91A polymorphism in AurkA/
STK15 causes a Phe31Ile substitution, and the 31Ile 
variant has been shown to be preferentially amplified 
and is associated with the degree of aneuploidy in human 
tumours. AurkA polymorphism has also been described as 
a genetic risk factor for the occurrence and progression of 
oesophageal tumours [17]. Moreover, a multiple cancer 
type meta-analysis revealed a significant cancer risk in 
both homozygotes and heterozygotes [18].
Recently, we found that patients characterised by 
elevated EGFR and elevated AurkA protein expression in 
tumour tissue represent a risk group with a poor disease-
free survival [19]. AurkA and EGFR share downstream 
signalling pathways, and each by itself represents a 
potential therapeutic target in HNSCC. In the present 
study, we determined the distribution of AurkA/STK15 
codon 91 homo- and heterozygosity in primary HNSCC 
and the associated non-neoplastic squamous epithelium. 
Moreover, we analysed the response to cetuximab and 
the inhibition of AurkA and AurkB in vitro according to 
AurkA/STK15 polymorphism. 
RESULTS
Elevated AurkA/B expression in HNSCC tissues
Immunohistochemical staining of HNSCC tissue 
revealed the overexpression of AurkA and AurkB 
compared to the corresponding healthy tissue (p < 0.05). 
The distribution of AurkA/STK15 codon 91 homo- and 
heterozygosity in the normal (n=64), non-neoplastic tissue 
of tumour patients (n=41) and tumour tissue (n=116) was 
determined by a restriction analysis of amplified AurkA/
STK15 cDNA. The heterozygous allele was found in 
37% and 33% of the normal and non-neoplastic tissues, 
respectively, whereas the portion increased to 49% in the 
tumour tissue (Suppl. Fig. 1). In addition, 10 HNSCC cell 
lines were analysed for the polymorphism, and a 50/50 
distribution was observed (Fig. 1). A heterozygous (HN) 
and homozygous wildtype (Cal27) HNSCC line were 
selected for further in vitro experiments; the genotype of 
codon 91 in these cell lines was verified by sequencing 
(Fig. 1). 
Cetuximab treatment impairs AurkA/STK15 
codon 91 polymorphism-dependent clonogenic 
survival 
It has been previously shown that cetuximab is 
a potent drug for the treatment of HNSCC [20, 21]. In 
Fig. 1: AurkA/STK15 Phe31Ile polymorphism analysis by PCR-RFLP and subsequent DNA sequencing. A total of 10 cell lines were 
tested and showed 50% Phe/Phe, 50% Phe/Ile, and 0% Ile/Ile.
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the present study, we tested 6 HNSCC lines for their 
susceptibility to cetuximab treatment. The Cal27, UD5, 
and UD7 cell lines showed a dramatic decrease in 
clonogenic survival after treatment, whereas the HN, UD3, 
and UD4 cells appeared to be resistant to cetuximab (Fig. 
2). Resistance to cetuximab treatment has been associated 
with the AurkA/STK15 Phe31Ile polymorphism. In 
contrast to the UD3, UD4, and HN cells, which harbour 
the polymorphism and did not respond to cetuximab 
treatment, the Phe31 homozygous wildtype UD5, UD7, 
and Cal27 cells (UD5 p = 0.0199; UD7 p = 0.0039; Cal27 
p = 0.0047) showed a significant decrease in clonogenic 
survival with antibody treatment. 
siRNA-mediated Aurora kinase A / B knockdown 
impairs clonogenic survival, independent of 
polymorphism
It has been shown that the inhibition of Aurora 
kinases overcomes resistance to cetuximab in HNSCC 
[19]. Therefore, we knocked down the expression of 
these kinases by treating the cells with an AurkA- or 
AurkB-specific small interfering RNA (siRNA). The 
siRNA-mediated knockdown of either AurkA or AurkB 
was highly effective (Suppl. Fig. 2) and specific; 
furthermore, the knockdown of AurkA did not affect the 
AurkB protein content and vice versa. The knockdown 
of each kinase caused a drastic and highly significant 
decrease in clonogenic survival (Fig. 3), an effect that was 
independent of AurkA polymorphism (Cal27 - siAurkA p 
= 0.0048, siAurkB p = 0.0084; HN - siAurkA p = 0.0004, 
siAurkB p = 0.0076). Treatment with the EGFR inhibitory 
antibody cetuximab also impaired clonogenic survival 
in the AurkA/STK15 Phe31Ile polymorphism-negative 
cell line Cal27 (p = 0.0047). Conversely, the HN cell 
line, which harbours the polymorphism, was resistant to 
cetuximab treatment with regard to clonogenic survival. 
To test the effect of the combined targeting of Aurora 
kinases and EGFR, both cetuximab and the AurkA/B-
specific siRNAs were applied, resulting in a further 
impairment of clonogenic survival in the Cal27 cells 
compared to the treatment with cetuximab alone. The 
combination treatment was also more effective than the 
knockdown alone, and the combination effect was even 
significantly increased with AurkB knockdown. The same 
effect was observed in the HN cells, though this cell line 
did not respond to cetuximab treatment alone (Fig. 3). 
Fig. 2: Resistance to cetuximab was associated with AurkA/STK15 Phe31Ile polymorphism (UD3, UD4, and HN). The cell lines 
UD5, UD7, and Cal27, which are homozygous wildtype for Phe31, exhibited a significant decrease in clonogenic survival.
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Induction of aneuploidy in HN cells upon AurkB 
knockdown but not by cetuximab treatment
Because Aurora kinases are important for the proper 
assembly of the spindle apparatus and chromosome 
segregation in mitosis, the effect of Aurora kinase 
knockdown on the ploidy of the cells was tested by flow 
cytometry. Aurk/B knockdown significantly resulted in 
15% aneuploid HN cells (p = 0.0314), which harbour the 
Phe31Ile polymorphism, whereas cetuximab treatment did 
not affect ploidy (Fig. 4). 
Combined treatment of cetuximab and Aurora 
kinase knockdown increases apoptosis
Apoptosis was detectable by flow cytometry after 
the knockdown of the respective Aurora kinase (Fig. 5). 
The knockdown of AurkB led to a significantly higher 
amount of apoptotic cells than the suppression of AurkA 
(Cal27 p = 0.0027; HN p = 0.0066). The Cal27 cells 
showed a trend of a higher amount of apoptotic cells upon 
treatments, though cetuximab treatment alone induced 
only a small but significant amount of apoptosis in these 
cells (p = 0.0267). This finding is in agreement with 
the decreased clonogenic survival in this cell line upon 
cetuximab treatment. The number of apoptotic cells could 
be further increased with high significance when combined 
with Aurora kinase knockdown. However, compared to the 
number of apoptotic cells already induced by the Aurora 
kinase knockdown, this increase was not significant, 
except for AurkA knockdown in Cal27 cells (p = 0.0342). 
Fig. 4: Treatment caused aneuploidy only in the HN cell line 
with the Phe31Ile polymorphism. The knockdown of AurkB 
had a significant impact on ploidy, whereas cetuximab treatment 
had no effect on ploidy.
Fig. 3: The knockdown of each kinase caused a drastic and highly significant decrease in clonogenic survival. The same effect was 
observed in HN cells, though this cell line did not response to cetuximab alone. 
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This observation indicates a higher importance of Aurora 
kinase knockdown, particularly AurkB, with respect to cell 
survival / cell death. 
Treatment with siRNA targeting AurkB causes 
enhanced apoptosis by reducing Akt activity
To identify the proteins involved in the regulation 
and control of cell proliferation and survival, a western 
blot analysis was performed after AurkA / AurkB siRNA 
and cetuximab treatments and their combination (Fig. 
6, Suppl. Fig. 3). As the activity of these proteins is 
typically regulated by posttranslational modifications, 
phosphorylation-specific antibodies were used. The EGFR, 
Akt, and Erk1/2 expression levels were not affected by any 
of the treatments. In the Cal27 but not HN cells, cetuximab 
resulted in a drastic increase in the phosphorylation of its 
target, EGFR, at Tyr1068. Akt phosphorylation at Ser473 
was significantly decreased upon AurkB knockdown 
in both cell lines; AurkB knockdown alone and in 
combination with cetuximab treatment resulted in an 
identical Akt phosphorylation state. 
Erk1/2 (a member of the MAP kinase family) 
phosphorylation at Thr202/Tyr204 was decreased upon 
AurkB knockdown in the Cal27 cells, in both the presence 
and absence of cetuximab. In the HN cells, the knockdown 
of each Aurora kinase caused a slight increase in Erk1/2 
phosphorylation, whereas the combination treatment 
decreased the amount of phosphorylated Erk1/2. 
Fig. 5:Apoptosis was detectable by flow cytometry after the knockdown of the respective Aurora kinase. The knockdown of AurkB 
led to a significantly higher number of apoptotic cells than AurkA suppression.
Fig. 6: According to western blot analyses, cetuximab treatment resulted in Tyr1068 phosphorylation of EGFR in cetuximab-
sensitive Cal27 cells. Moreover, we found a downregulation of Akt after treatment with an siRNA against AurkB in both cell lines.
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DISCUSSION
HNSCC is the sixth most common cancer worldwide 
[1] and typically has a poor prognosis. Unfortunately, new 
therapeutic regimens, e.g., the combination of standard 
(chemo-) therapies with cetuximab treatment, merely 
prolong the overall survival by a few months [20], and 
therapy response to cetuximab treatment can only be 
insufficiently evaluated by cutaneous side effects [22, 
23]. Because Aurora kinases are frequently upregulated 
in HNSCC and EGFR is often expressed, both of these 
molecules represent attractive therapeutic targets. In this 
study, we investigated the role of Aurora kinases A and 
B on tumour cell survival and apoptosis in HNSCC in 
vitro. Furthermore, we examined the impact of AurkA 
polymorphism on the susceptibility of HNSCC to 
cetuximab treatment. 
We confirmed the observation that the AurkA and 
AurkB proteins are significantly overexpressed in HNSCC 
tissues [24-29], and it has been demonstrated that an 
upregulation of AurkA mRNA and protein in HNSCC 
is associated with a poor outcome [30]. Moreover, it has 
been shown that AurkA overexpression and/or dysfunction 
results in chromosomal instability through abnormal 
spindle formation and defects in cytokinesis, resulting 
in aneuploidy [31-34]. Accordingly, these genomically 
altered cells can promote tumour progression, with a 
poor disease outcome. We previously demonstrated 
that a subgroup of HNSCC patients with reduced DFS 
and a particularly poor prognosis is characterised by 
concomitant AurkA and EGFR overexpression [19].
Our RFLP analysis revealed the distribution of 
AurkA polymorphism in HNSCC specimens (48% Phe/
Phe, 49% Phe/Ile, and 3% Ile/Ile) and normal tissues 
(67% Phe/Phe, 33% Phe/Ile, and 0% Ile/Ile). Although 
the Phe/Phe polymorphism is common and the Phe/Ile 
variant is more frequently found in tumour tissues, no 
correlation of either variant with the course or outcome 
of the disease could be found. Nevertheless, the AurkA 
polymorphism has been observed in many tumour types, 
e.g., oesophageal, breast, hepatocellular, and prostate 
cancer [17, 35-38]. Miao et al. found a 44.2% frequency 
of the heterozygous allele in oesophageal tumour patients, 
the same range as found in the present study (49%). In 
contrast, the frequency of the Ile/Ile polymorphism found 
in other tissues was clearly higher at 47.0% [17]. The 
prognostic value of either polymorphism, however, is 
unclear and remains controversial [17, 35-38]. 
Although we found a reduced capacity to form cell 
colonies in the presence of the Phe/Ile polymorphism, 
which was associated with cetuximab resistance, the 
clinical studies to date do not suggest any correlation 
between STK15/AurkA polymorphism and cetuximab 
treatment resistance. Astsaturov et al., however, identified 
EGFR downstream signalling molecules involved in the 
resistance to cetuximab treatment. These authors observed 
synergistic treatment efficiency by a pronounced decrease 
in cell viability and tumour size upon simultaneous AurkA 
and EGFR targeting, revealing evidence for AurkA / 
EGFR signalling crosstalk [39]. In addition, an increased 
rate of relapse, a poorer response rate, and shortened 
disease-free and median survival rates have been reported 
for oesophageal carcinoma patients with the Phe/Ile 
polymorphism who were treated with chemo-radiotherapy 
followed by surgery [40]. Hence, there is accumulating 
evidence for the involvement of the heterozygous Aurora 
kinase polymorphism Phe/Ile in disease outcome and 
anti-EGFR/anti-Aurora kinase treatment susceptibility. 
Although, we connected data which were collected by the 
retrospective analysis of (primary) tissues taken ex-vivo 
and data derived from well characterized HNSCC cell 
lines our findings need to be corroborated by prospective 
clinical trials. 
Our analyses of clonogenic survival revealed that the 
STK15/AurkA homozygous Cal27, UD5, and UD7 cells 
efficiently respond to cetuximab mono-treatment, whereas 
the heterozygous HN, UD3, and UD4 cells do not. The 
homozygous Cal27 and heterozygous HN cells exhibited 
a decreased clonogenic survival after the knockdown of 
both AurkA and AurkB, and apoptosis was largely induced 
in the Cal27 cells by all the treatment regimens against 
EGFR or AurkA / B. The efficiency of the combined 
treatment was additive in the Cal27 cells, and, even 
more importantly, cetuximab resistance in the HN cells 
was abolished by AurkA / B knockdown. The overall 
efficiency of the combined anti-EGFR/anti-Aurora kinase 
treatment reached a similar level in the heterozygous 
and homozygous cell lines. The enhanced treatment 
efficiency can possibly be explained by the cetuximab-
related inhibition of EGFR/STAT5A interactions, which 
intensified the siRNA-mediated knockdown of AurkA 
expression by the cetuximab functional knockdown of any 
remaining AurkA protein [41]. The heterozygous HN cells 
but not homozygous Cal27 cells developed aneuploidy 
after AurkA / B knockdown, a phenomenon that suggests 
at least in part different response mechanisms, which can 
likely be attributed to AurkA polymorphism and a greater 
degree of chromosomal instability in HN cells.
In the Cal27 cells, we found that cetuximab 
treatment induced Tyr1068 EGFR-phosphorylation, which 
has been previously associated with treatment response 
[42]. Regardless of EGFR phosphorylation, both the Cal27 
and HN cells showed reduced Akt activation upon AurkB 
knockdown that strongly correlated with reduced cell 
survival. The AurkA knockdown, however, did not affect 
the EGFR downstream survival pathway. In addition, pan-
inhibition of Aurora kinases by cell treatment with VX-
680, causes pronounced AurkB inhibition [43], suppresses 
Akt-1 activation and inhibits cell proliferation [44]. 
Thus, the MAPK-related proliferation pathway was only 
affected by the combined treatment with siRNA against 
AurkB (but not AurkA) and cetuximab. Sharma et al. 
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demonstrated that AurkB is a downstream target of B-raf 
in melanoma and inhibition of AurkB lead to a reduced 
tumor development [45]. These findings could explain the 
outcome of combined AurkB targeting. 
Taken together, the data indicate that both the 
EGFR and Aurora kinases seem to play important roles 
in the tumour biology and treatment of HNSCC. Further 
knowledge of the molecular mechanisms underlying 
simultaneous EGFR / Aurora kinase targeting will 
facilitate the design of the most efficient therapeutic 
strategies in consideration of AurkA polymorphism.
CONCLUSION
Thus far, the response to cetuximab-based anti-
EGFR therapy can only be estimated by the degree of 
skin reactions; markers that can reliably predict therapy 
efficiency have not yet been described. Here, we provide 
evidence that AurkA genotypically homozygous HNSCC 
cells respond to cetuximab mono-treatment, whereas 
heterozygous cells do not. Moreover, cetuximab resistance 
can be overcome by siRNA-based AurkA / B knockdown 
in vitro. The combination of cetuximab and anti-AurkA/B 
targeting in HNSCC cells ameliorates any polymorphism-
related difference and increases the treatment efficiency, 
independent of the Aurora kinase genotype. However, 
the efficiency of such a therapy as a function of AurkA 
polymorphism remains to be investigated more extensively 
in a clinical setting. A translational approach will enable 
the identification of patients who may potentially benefit 
from cetuximab treatment alone and those who require 
additional modular targeting.
MATERIAL AND METHODS
Tissue samples
Formalin-fixed and paraffin-embedded (FFPE) 
tumour samples from 264 patients with a squamous cell 
carcinoma of the oral cavity (n=42), oropharynx (n=101), 
hypopharynx (n=49), or larynx (n=72) were examined for 
AurkA and AurkB expression. The expression levels were 
compared to the non-cancerous tissues from some of the 
same patients (matched pairs). This study was approved by 
the Medical Ethics Committee of the Technical University 
of Munich (project number 1420/05). 
Tissue microarray preparation
Core needle biopsies from representative areas of 
each tumour specimen were retrieved from the original 
tumour blocks using a manual array (Beecher Instruments, 
Sun Prairie, Wisconsin, USA) and placed in a recipient 
paraffin array block; we obtained at least three tissue 
cylinders, with a diameter of 0.6 mm, from each biopsy 
specimen.
Tissue microarrays and protein analyses 
An HNSCC tissue microarray (TMA) containing 
tumour tissues with representative areas of interest and 
non-neoplastic squamous epithelium was used for the 
protein analyses. The TMA was sectioned, placed on 
coated glass slides, and deparaffinised for the subsequent 
procedures.
Immunohistochemical study
Fresh 1.5 µm sections from the TMA blocks were 
transferred to glass slides, deparaffinised, and rehydrated. 
For antigen retrieval, the slides were heated in citrate-
buffered saline (pH=6), and the slides were incubated 
for 1 hour with antibodies against Aurora kinase A 
(rabbit, clone D38B1, 1:200; Cell Signaling Technology, 
Frankfurt, Germany) and Aurora kinase B (rabbit, 1:200; 
Cell Signalling Technology, Frankfurt, Germany). The 
reaction was developed using the labelled streptavidin-
biotin-peroxidase system. After counterstaining with 
haematoxylin, the slides were dehydrated in ascending 
ethanol concentrations and mounted. Tissues with known 
expression of the respective antigen were used as positive 
controls; immunoglobulin isotypes were used as negative 
controls.
The staining intensity and patterns were rated by 
the following scoring system for the semiquantitative 
estimation of expression levels: from 0 to 3 points (0 
points = no staining, 1 point = low staining intensity, 2 
points = moderate staining intensity, 3 points = strong 
staining intensity). Additionally, the fraction of stained 
cells was determined and graded from 0 to 4 points (0 
points = 0% of the tumour cells, 1 points = <10% of the 
tumour cells, 2 points = 10%-29% of the tumour cells, 3 
points = 30%-59% of the tumour cells, 4 points = 60%-
100% of the tumour cells). Both the staining intensity and 
fraction of stained cells were added together to generate a 
score from 0 to 7.
AurkA/STK15 polymorphism analyses: PCR-
restriction fragment length polymorphism 
(RFLP)
DNA was isolated from cell lines (n=10) and the 
FFPE tumour (n=116) and control (n=64) samples using 
the DNeasy Kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions. 
The specific PCR for AurkA genotypes at the 
Phe31Ile site was performed using the Taq-DNA 
Polymerase all-inclusive Kit (PeqLab, Erlangen, Germany) 
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according the manufacturer’s guidelines. We applied the 
following thermocycler (BioRad, Munich, Germany) 
PCR programme: (95°C for 5 min, 30 cycles of 95°C for 
30 s, 60°C annealing for 30 s, and 72°C for 30 s), and 
72°C for 7 min. The following primers were used: AurkA/
STK15 forward, CTTTCATGAATGCCAGAAAGTT, and 
reverse, CTGGGAAGAATTTGAAGGACA.
The 165-bp PCR products were digested with 
ApoI (New England BioLabs, Inc., Beverly, USA) and 
separated on a 2.5% agarose gel. Digestion of the AurkA/
STK15 31Phe allele results in two fragments (153 bp and 
12 bp), whereas the AurkA/STK15 31Ile allele contains an 
additional third ApoI restriction site and thus three bands 
(89 bp, 64 bp, and 12 bp) are generated after digestion. 
The results were further confirmed by DNA sequencing 
using an ABI 3100 DNA sequencer (Life Technologies, 
Darmstadt, Germany).
Cell culture
The Cal27 and HN cell lines were obtained 
from DSMZ (Braunschweig, Germany), and the UD3, 
UD4, UD5, and UD7 cell lines were obtained from the 
University of Düsseldorf. The AurkA polymorphism status 
of the cell lines is shown in Fig. 1. Additionally, all cell 
lines present a moderate expression of EGFR by western 
blot analyses. The cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Invitrogen, Darmstadt, 
Germany) containing 10% foetal calf serum (FBS) 
(Biochrom, Berlin, Germany), 2 mM glutamine, 100 µg/
ml streptomycin, and 100 U/ml penicillin (Biochrom, 
Berlin, Germany), maintained at 37 °C in an atmosphere 
of 5% CO2, and grown to 70-90% confluence.
RNA interference
Cal27 and HN cells were seeded in 6-well 
tissue culture dishes in a medium containing serum 
and antibiotics. Shortly before transfection, the 
medium was changed to OptiMEM. A mixture of 4 μl 
OligofectamineTM Transfection Reagent (Invitrogen, 
Frankfurt, Germany) and 30 nM Stealth RNAiTM siRNA 
duplex oligoribonucleotides in OptiMEM was added, and 
the cells were incubated for 48 hours before seeding for 
further investigation. siRNA duplex oligoribonucleotides 
targeting AurkA (primer AURKAHSS1861148) and 
AurkB (primer AURKBHSS90047) were obtained from 
Invitrogen. The knockdown efficiency was monitored by 
western blotting.
Inhibitors
The mouse-human chimeric EGFR-inhibitory 
antibody cetuximab was purchased from Merck, 
Darmstadt, and 140 nM cetuximab was used to treat the 
cells.
Colony formation assay
Cell survival was assessed by a colony formation 
assay. The cells were seeded in 6-well tissue culture dishes 
(5 × 102 cells/well); after 1 d, the Aurora A / B-knockdown 
cells and control cells were treated with cetuximab (140 
nM) and cultured. After 10 days, the cell colonies were 
subsequently formalin fixed and visualised by crystal 
violet staining (Sigma-Aldrich, Steinheim, Germany); the 
colonies were counted manually.
Flow cytometry
All flow cytometric analyses were performed using 
the FACSCanto-II flow cytometer (BD Biosciences, 
San Jose, CA, USA) equipped with a blue (488 nm), a 
red (633 nm), and a violet (405 nm) laser and a standard 
optical configuration. A 530/30 bandpass filter, a 670-nm 
longpass filter, and a 450/50 bandpass filter were installed 
for green (FITC), red (PI), and blue (Dapi) fluorescence 
detection, respectively. The data acquisition and analysis 
were performed with the FACSDiva software (Ver. 6.1.1, 
BD Biosciences, San Jose, CA, USA). 
Flow cytometric quantification of apoptosis
An AnnexinV/propidium iodide (PI) assay was 
employed to quantify the induction of apoptosis by the 
individual treatment (cetuximab, siAurkA, siAurkB, and 
combinations). This assay enabled the quantification 
of vital (AnnexinV/PI negative), early (AnnexinV 
positive/PI negative), and late apoptotic (AnnexinV/PI 
double positive) cells at each measurement. The cells 
were seeded, incubated, and treated as described above. 
After 24 hours and 48 hours growth intervals, the cells 
were harvested by trypsinisation, and the cell culture 
supernatant (potential dead and detached cells) of each 
sample was collected and pooled with the harvested 
cells. Untreated cells served as a negative control. The 
cells were immediately stained after harvesting using 
the TACSTM AnnexinV-FITC Apoptosis Detection Kit 
(R&D Systems, Wiesbaden-Nordenstadt, Germany) 
according to the manufacturer’s instructions. Single-
colour controls (unlabelled, AnnexinV-FITC-labelled, 
and PI only-labelled cells) were used in combination with 
double-stained samples (AnnexinV-FITC/PI-labelled 
cells) for compensation controls (compensation matrix, 
FITC-PI 7.3% and PI-FITC 0.067%; automatic software 
compensation). Quadrant statistics revealed the fraction 
of vital and apoptotic cells for each sample (the early and 
late apoptotic cells were counted as one fraction of dead 
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/ apoptotic cells). All the experiments were performed in 
triplicate.
Aneuploidy assay
To quantify the fraction of aneuploid cells, the 
treated cells were harvested, washed once with PBS, 
fixed overnight with 70% methanol, washed again, and 
resuspended in PBS containing 0.01 mg/ml RNase (Sigma 
Bio-Sciences, Deisenhofen, Germany). The cells were 
incubated at 37 °C for 30 min. The cell preparation was 
completed by the addition of 4’,6-diamidino-2-phenylindol 
(DAPI, Sigma Bio-Sciences) at a final concentration of 1 
µg/ml. The DAPI fluorescence signal, as measured by flow 
cytometry, was plotted on a linear scale, and the ploidy 
analysis was performed using the multi-cycle algorithm 
of the ModFit LT 3.2 software (Verity Software House, 
Topsham, ME, USA), with cell doublet, aggregate, and 
debris discrimination via pulse processing. 
Western blotting
The cells were lysed in lysis buffer (New England 
Biolabs, Frankfurt, Germany) supplemented with 1 mM 
PMSF (Roth, Karlsruhe, Germany). Equal amounts 
of protein (15 μg) were separated by SDS-PAGE and 
transferred to Immobilon PVDF membranes (Millipore, 
Schwalbach, Germany). The blocking of nonspecific 
binding sites was performed using 5% (w/v) non-fat 
dry milk in TBST. The membranes were then incubated 
with primary antibodies diluted in 5% non-fat dry 
milk/ TBST for 12-14 hours at 4 °C. HRP-conjugated 
immunoglobulins (diluted 1:5000 in 5% non-fat dry 
milk/TBST) were used as the secondary antibodies and 
incubated for 1 h at room temperature. Immunoreactivity 
was visualised using the Pierce ECL Western Blotting 
Substrate (Thermo Scientific) and exposure to high-
performance chemiluminescence film (G&E Healthcare, 
Freiburg, Germany). 
Statistical analyses
For interpretation of the immunohistochemical and 
PCR-RFLP data, statistical analyses were performed using 
SPSS software (version 18/19, IBM). A significance level 
of 5% was determined for all the statistical tests. First, 
the expression profiles of each marker in the different 
subgroups were compared (tumour versus normal tissue) 
using a nonparametric test (Wilcoxon-Mann-Whitney-
Test). The overall survival was analysed by Kaplan-Meier 
curves and a log rank test. 
Statistical analyses of the results from the in vitro 
experiments were performed using the Prism Graph Pad 
5.0 software. Results with p-values < 0.05 were considered 
significant.
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